Caprock Group Reduces Liquidia Stake in Q1
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 59 minutes ago
0mins
Should l Buy LQDA?
Source: Fool
- Share Reduction Transaction: Caprock Group sold 416,686 shares of Liquidia in Q1 2026, with an estimated transaction value of $15.46 million, indicating a strategic adjustment in its holding approach towards Liquidia.
- Position Change: After the sale, Caprock's Liquidia holdings decreased to 1,367,235 shares valued at $51.60 million, with a net position change reflecting a decrease of $9.93 million, suggesting a focus on managing investment risk.
- Performance Highlights: Liquidia generated approximately $130 million in YUTREPIA sales during Q1, achieving a net income of $53 million, demonstrating an accelerating commercialization process and marking its third consecutive profitable quarter.
- Market Performance: Liquidia's stock price surged nearly 260% over the past year, significantly outperforming the S&P 500's 26% gain, reflecting strong market demand for its innovative therapies and potential for future growth.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LQDA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LQDA
Wall Street analysts forecast LQDA stock price to fall
8 Analyst Rating
8 Buy
0 Hold
0 Sell
Strong Buy
Current: 56.600
Low
31.00
Averages
47.50
High
67.00
Current: 56.600
Low
31.00
Averages
47.50
High
67.00
About LQDA
Liquidia Corporation is a biopharmaceutical company. The Company is focused on the development, manufacture and commercialization of products that address unmet patient needs, with a focus directed towards rare cardiopulmonary diseases, such as pulmonaryarterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The Company operate through its wholly owned operating subsidiaries, Liquidia Technologies, Inc. and Liquidia PAH, LLC. Its proprietary PRINT technology is a particle engineering platform, which enable precise production of uniform drug particles. Its lead product candidate is YUTREPIA for the treatment of PAH and PH-ILD. YUTREPIA is an inhaled dry powder formulation of treprostinil designed with PRINT to improve the therapeutic profile of treprostinil by enhancing deep lung delivery while using a convenient, dry-powder inhaler (DPI) and by achieving higher dose levels than the labeled doses of current inhaled therapies.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Liquidia Corp Reports Strong Q1 Earnings Exceeding Expectations
- Strong Performance: Liquidia Corp reported Q1 earnings of $0.52 per share, exceeding market expectations, which demonstrates the company's robust performance in the biopharmaceutical sector and is likely to boost investor confidence.
- Sales Growth: The company achieved sales of $132.865 million, significantly increasing compared to the same period last year, reflecting the competitiveness and sustained demand for its products, which may drive future revenue growth.
- Analyst Optimism: Several analysts have raised their price targets for Liquidia Corp stock, indicating an increased market confidence in its future performance, which could attract more investor interest in the stock.
- Positive Market Reaction: Due to the better-than-expected results and analysts' optimistic outlook, Liquidia Corp's stock is likely to experience a positive market reaction in the short term, further driving up its share price.
See More
Caprock Group Reduces Liquidia Stake in Q1
- Share Reduction Transaction: Caprock Group sold 416,686 shares of Liquidia in Q1 2026, with an estimated transaction value of $15.46 million, indicating a strategic adjustment in its holding approach towards Liquidia.
- Position Change: After the sale, Caprock's Liquidia holdings decreased to 1,367,235 shares valued at $51.60 million, with a net position change reflecting a decrease of $9.93 million, suggesting a focus on managing investment risk.
- Performance Highlights: Liquidia generated approximately $130 million in YUTREPIA sales during Q1, achieving a net income of $53 million, demonstrating an accelerating commercialization process and marking its third consecutive profitable quarter.
- Market Performance: Liquidia's stock price surged nearly 260% over the past year, significantly outperforming the S&P 500's 26% gain, reflecting strong market demand for its innovative therapies and potential for future growth.
See More
Liquidia (LQDA) Q1 2026 Earnings Transcript
See More
JW Asset Management Sells Liquidia Shares
- Share Reduction Transaction: On May 8, 2026, JW Asset Management sold 83,600 shares of Liquidia Corporation, with an estimated transaction value of $3.10 million, reducing its stake to 0.25% of its total U.S. equity assets.
- Value Change in Holdings: Following the sale, JW Asset Management's holdings in Liquidia decreased to 16,176 shares worth $610,482, with a net position value decline of $2.83 million during the period, indicating a potential loss of confidence in the company.
- Strong Market Performance: As of May 7, 2026, Liquidia shares were priced at $42.28, reflecting a 175% increase over the past year, significantly outperforming the S&P 500 by approximately 145 percentage points, showcasing its robust position in the biopharmaceutical market.
- Sales Growth of Products: Liquidia's inhaled drug YUTREPIA generated $148.3 million in net product sales in 2025, including $90.1 million in the fourth quarter alone, indicating strong market demand in the pulmonary arterial hypertension treatment sector.
See More
Liquidia Q1 Earnings Preview: Significant Revenue Growth Expected
- Earnings Announcement Date: Liquidia (LQDA) is set to release its Q1 earnings on May 11 before market open, with a consensus EPS estimate of $0.41, reflecting a substantial year-over-year increase of 191.1%, indicating a significant improvement in profitability.
- Revenue Surge Expected: The anticipated revenue for Liquidia in Q1 is $116.59 million, representing a staggering year-over-year growth of 3636.9%, which highlights the strong demand and sales growth potential of its products in the market.
- Performance Forecast Revisions: Over the past year, Liquidia has not met EPS estimates at all, while it has achieved revenue estimates 25% of the time, indicating volatility in revenue performance, although recent EPS estimates have seen one upward revision and two downward adjustments.
- Market Share Growth: Liquidia's YUTREPIA product has captured a 17% market share in Q4, with the company targeting a $1 billion franchise by 2027, demonstrating its robust growth potential in the mid-cap healthcare sector.
See More
Liquidia Corporation Emerges as Top Stock Pick with Significant Upside
- Holding Changes: Farallon Capital first held 1.8 million shares of Liquidia in Q2 2020, reestablishing a position of 2 million shares in Q1 2024, and increasing to 8.6 million shares by Q4 2025, reflecting sustained confidence and investment potential in the company.
- Market Performance: Liquidia reported $90.1 million in product sales for Q4 2025, a 74% increase from Q3, indicating rapid adoption of its product YUTREPIA in the pulmonary hypertension market, further solidifying its market position.
- Industry Outlook: Viewed as a disruptive force in the pulmonary hypertension market, Liquidia faces litigation from United Therapeutics, yet its transition to profitability and expansion of its sales force targeting over 860 active prescribers signal strong future growth potential.
- Strategic Goals: CEO Roger Jeffs confirmed a clear path for Liquidia to achieve $1 billion in revenue by 2027, showcasing the company's robust growth prospects and investment appeal in the biopharmaceutical sector.
See More
Liquidia Corp Reports Strong Q1 Earnings Exceeding Expectations
- Strong Performance: Liquidia Corp reported Q1 earnings of $0.52 per share, exceeding market expectations, which demonstrates the company's robust performance in the biopharmaceutical sector and is likely to boost investor confidence.
- Sales Growth: The company achieved sales of $132.865 million, significantly increasing compared to the same period last year, reflecting the competitiveness and sustained demand for its products, which may drive future revenue growth.
- Analyst Optimism: Several analysts have raised their price targets for Liquidia Corp stock, indicating an increased market confidence in its future performance, which could attract more investor interest in the stock.
- Positive Market Reaction: Due to the better-than-expected results and analysts' optimistic outlook, Liquidia Corp's stock is likely to experience a positive market reaction in the short term, further driving up its share price.
See More
Caprock Group Reduces Liquidia Stake in Q1
- Share Reduction Transaction: Caprock Group sold 416,686 shares of Liquidia in Q1 2026, with an estimated transaction value of $15.46 million, indicating a strategic adjustment in its holding approach towards Liquidia.
- Position Change: After the sale, Caprock's Liquidia holdings decreased to 1,367,235 shares valued at $51.60 million, with a net position change reflecting a decrease of $9.93 million, suggesting a focus on managing investment risk.
- Performance Highlights: Liquidia generated approximately $130 million in YUTREPIA sales during Q1, achieving a net income of $53 million, demonstrating an accelerating commercialization process and marking its third consecutive profitable quarter.
- Market Performance: Liquidia's stock price surged nearly 260% over the past year, significantly outperforming the S&P 500's 26% gain, reflecting strong market demand for its innovative therapies and potential for future growth.
See More
Liquidia (LQDA) Q1 2026 Earnings Transcript
See More
JW Asset Management Sells Liquidia Shares
- Share Reduction Transaction: On May 8, 2026, JW Asset Management sold 83,600 shares of Liquidia Corporation, with an estimated transaction value of $3.10 million, reducing its stake to 0.25% of its total U.S. equity assets.
- Value Change in Holdings: Following the sale, JW Asset Management's holdings in Liquidia decreased to 16,176 shares worth $610,482, with a net position value decline of $2.83 million during the period, indicating a potential loss of confidence in the company.
- Strong Market Performance: As of May 7, 2026, Liquidia shares were priced at $42.28, reflecting a 175% increase over the past year, significantly outperforming the S&P 500 by approximately 145 percentage points, showcasing its robust position in the biopharmaceutical market.
- Sales Growth of Products: Liquidia's inhaled drug YUTREPIA generated $148.3 million in net product sales in 2025, including $90.1 million in the fourth quarter alone, indicating strong market demand in the pulmonary arterial hypertension treatment sector.
See More
Liquidia Q1 Earnings Preview: Significant Revenue Growth Expected
- Earnings Announcement Date: Liquidia (LQDA) is set to release its Q1 earnings on May 11 before market open, with a consensus EPS estimate of $0.41, reflecting a substantial year-over-year increase of 191.1%, indicating a significant improvement in profitability.
- Revenue Surge Expected: The anticipated revenue for Liquidia in Q1 is $116.59 million, representing a staggering year-over-year growth of 3636.9%, which highlights the strong demand and sales growth potential of its products in the market.
- Performance Forecast Revisions: Over the past year, Liquidia has not met EPS estimates at all, while it has achieved revenue estimates 25% of the time, indicating volatility in revenue performance, although recent EPS estimates have seen one upward revision and two downward adjustments.
- Market Share Growth: Liquidia's YUTREPIA product has captured a 17% market share in Q4, with the company targeting a $1 billion franchise by 2027, demonstrating its robust growth potential in the mid-cap healthcare sector.
See More
Liquidia Corporation Emerges as Top Stock Pick with Significant Upside
- Holding Changes: Farallon Capital first held 1.8 million shares of Liquidia in Q2 2020, reestablishing a position of 2 million shares in Q1 2024, and increasing to 8.6 million shares by Q4 2025, reflecting sustained confidence and investment potential in the company.
- Market Performance: Liquidia reported $90.1 million in product sales for Q4 2025, a 74% increase from Q3, indicating rapid adoption of its product YUTREPIA in the pulmonary hypertension market, further solidifying its market position.
- Industry Outlook: Viewed as a disruptive force in the pulmonary hypertension market, Liquidia faces litigation from United Therapeutics, yet its transition to profitability and expansion of its sales force targeting over 860 active prescribers signal strong future growth potential.
- Strategic Goals: CEO Roger Jeffs confirmed a clear path for Liquidia to achieve $1 billion in revenue by 2027, showcasing the company's robust growth prospects and investment appeal in the biopharmaceutical sector.
See More
